Renault to Sell Back $824 Million Stake to Nissan as It Seeks Rating Upgrade — Update
By Adria Calatayud and David Sachs
Renault plans to sell a 5% stake in Nissan Motor back to the Japanese carmaker for up to 765 million euros ($823.6 million), commencing a draw-down of its shares as part of a plan to gain an investment-grade rating.
The French company said Tuesday that the sale of the Nissan shares could result in a capital loss of up to EUR1.5 billion which would hit net profit in its own accounts. This is the maximum amount and could be adjusted at year-end, Renault said.
Renault, which has a stake of around 43% in Nissan, aims to whittle its holdings down to about 15% as part an agreement between the longtime partners to thin out their relationship. Tuesday's sale commenced that process, which Renault hopes will help it achieve an investment-grade rating, Bernstein analysts said in a research note.
Bernstein said the deal could grow Renault's cash balance by around EUR4.2 billion.
Renault said the 5% stake in Nissan it is selling back to its Japanese partner is part of a 28.4% stake it transferred to a French trust last month. The sale will be implemented as part of a Nissan share buyback.
Renault's estimates for the value of the sale and its expected impact assume 211 million Nissan shares are sold at a share price of 568.5 Japanese yen ($3.89),it said.
Write to Adria Calatayud at adria.calatayud@dowjones.com and to David Sachs at david.sachs@wsj.com
(END) Dow Jones Newswires
December 12, 2023 07:40 ET (12:40 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
5 Stocks to Buy That We Still Like After They’ve Run Up
-
Markets Brief: Stocks Are Starting to Look Cheap Again
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track
-
American Airlines Earnings: We See Costs Overshadowing Market Share This Year
-
Snap Earnings: Advertising Growth and Snapchat+ Drive Monetization
-
STMicro Earnings: We Still See an Attractive Margin of Safety Despite a Poor First-Half Forecast
-
Alphabet Shares Surge on Strong Earnings, Dividend Surprise
-
Microsoft Earnings: Firm Beats Forecasts on Strong AI and Cloud Demand
-
PG&E Earnings: Near-Term Regulatory Certainty Supports Industry-Leading Earnings Growth